Depression in Schizophrenia: Perspective in the Era of “Atypical” Antipsychotic Agents

Siris, Samuel G.

doi:10.1176/appi.ajp.157.9.1379

Cited by 374 publications

(278 citation statements)

References 141 publications

Supporting

Mentioning

244

Contrasting

Unclassified

Order By: Relevance

“…This finding confirms previous similar studies elsewhere. [1][2][3] The Epidemiologic Catchment Area (ECA) study indicated that patients with schizophrenia were 29 times more likely than the general population to have a lifetime diagnosis of major depression. 22 Similarly, the National Comorbidity Study (NCS) suggested that 59% of patients with schizophrenia met DSM-III criteria for major or minor depression.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Rate of depression among patients with schizophrenia

Rahim

2016

ZJMS

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

“…1 The prevalence rates differ noticeably depending on the phase of the illness as well as the assessment tools implemented. A wide range of prevalence rates have been reported between 7% and up to 75%.…”

Section: Introductionmentioning

confidence: 99%

Rate of depression among patients with schizophrenia

Rahim

2016

ZJMS

View full text Add to dashboard Cite

show abstract

“…Os sintomas depressivos podem ocorrer em todas as fases da esquizofrenia, especialmente na depressão pós-psicótica, podendo contribuir para os sintomas residuais da doença, segundo os quais a proporção de pacientes com esquizofrenia que também manifestam a depressão varia de 7% a 75% (Siris, 2000). Os sintomas depressivos precisam ser diferenciados dos efeitos colaterais das medicações antipsicóticas (incluindo a disforia induzia pela medicação, a acinesia e a acatisia), e dos sintomas negativos primários da esquizofrenia (APA, 2004).…”

Section: Sintomas Depressivosunclassified

“…Os antidepressivos tricíclicos (ADT) têm sido avaliados primariamente no tratamento da depressão pós-psicótica (Nível B) . Também se descobriu que outros antidepressivos (como os ISRS e os duplos inibidores da recaptação) são úteis no tratamento da depressão na esquizofrenia (Nível B) (Siris, 2000). Ainda, em outro ECR, não foi observada nenhuma vantagem significativa com a sertralina quando comparada ao placebo, havendo alto índice de resposta ao placebo (Addington et al, 2002).…”

Section: Sintomas Depressivosunclassified

Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 2: tratamento de longo prazo

Falkai¹,

Wobrock²,

Lieberman³

et al. 2006

Rev. psiquiatr. clín.

View full text Add to dashboard Cite

ResumoEstas diretrizes para o tratamento biológico da esquizofrenia foram desenvolvidas pela Força-Tarefa da Federação Mundial das Sociedades de Psiquiatria Biológica (World Federation of Societies of Biological Psychiatry, WFSBP). As metas fixadas durante o desenvolvimento destas diretrizes foi a revisão sistemática de todas as evidências disponíveis referentes ao tratamento da esquizofrenia, tanto no âmbito clínico como no científico, e o estabelecimento de um consenso sobre as principais recomendações para a prática psiquiátrica. Estas diretrizes são destinadas a todos os médicos que atendem e tratam de pacientes portadores de esquizofrenia. Os dados usados para desenvolver estas diretrizes foram extraídos primariamente de vários painéis e diretrizes nacionais para o tratamento da esquizofrenia, assim como de metanálises, revisões e estudos clínicos randomizados sobre a eficácia do tratamento farmacológico e de outras intervenções terapêuticas biológicas, identificadas por uma busca nas bases de dados MedLine e na Biblioteca Cochrane. A literatura identificada

show abstract

“…7 It must be stressed that these conceptual bases are not mutually exclusive and that, in addition, areas of common functions between different atypical as well as first generation antipsychotics have been considered instrumental to our identification of shared pathophysiological dimensions of schizophrenia, including negative symptoms, and depression. 8 For instance, different depressive states, irrespective of their diagnostic categorization, share in common the incapacity to anticipate, seek and consume 'pleasures' (ie conditions that produce reward) and a decreased cognitive ability to properly perform in everyday life, suggesting a possible common neurobiological basis between 'emotions' and cognition.…”

Section: Introductionmentioning

confidence: 99%

The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia

Pani

Gessa

2002

Mol Psychiatry

View full text Add to dashboard Cite

In this paper the historical and scientific background that led to the use of substituted benzamides in two apparently unrelated clinical conditions namely dysthymic disorder and schizophrenia will be reviewed, in order to understand if a common mechanism of action may support this dual therapeutic indication. The dopaminergic antidepressant action of substituted benzamides such as sulpiride, has been proposed, since the late 1970s, by several authors and extensively explored in preclinical experiments by our group. In Italy the first marketing authorization obtained for the new substituted benzamide amisulpride, was with the sole indication of dysthymia and therefore a solid clinical experience exists in the use of substituted benzamides in mild forms of depression, with more than 1 000 000 patients being treated in the last 7 years. The proposed mechanism of action of substituted benzamides implies a selective modulation of the dopaminergic system in the mesocorticolimbic area, important for cognitive processing of internal and external cues, related to survival. The selective antagonism of dopamine D2-D3 receptors has been evoked to explain, in small to moderate doses (ie 50-100 mg day −1 ), the antidepressant effect and, in moderate to medium doses (100-400 mg day −1 ), the reported efficacy on negative symptoms of schizophrenia. Thus, substituted benzamides could represent the first class of atypical antipsychotics successfully employed for both depressive states and schizophrenia. Interestingly, recent evidence in the literature suggests that depressive episodes belonging to the bipolar spectrum are among 'alternative indications' of other atypical antipsychotics such as olanzapine and risperidone.

show abstract

Depression in Schizophrenia: Perspective in the Era of “Atypical” Antipsychotic Agents

Cited by 374 publications

References 141 publications

Rate of depression among patients with schizophrenia

Rate of depression among patients with schizophrenia

Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 2: tratamento de longo prazo

The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia

Contact Info

Product

Resources

About